Novartis | NVS - Gross Profit On Sales


Novartis reported $10.82B in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Bausch Health Companies USD 1.93B 165M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Corcept Therapeutics USD 199.58M 3.46M Dec/2025
Drreddys Laboratories INR 46.81B 10.24B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
J&J USD 16.6B 118M Dec/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Pacira USD 130.92M 5M Sep/2025
Perrigo USD 377.1M 14.2M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Phibro Animal Health USD 101.87M 18.38M Dec/2024
Prestige Brands USD 157.37M 5.79M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sanofi EUR 8.45B 3.02B Dec/2025
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
Zoetis USD 1.64B 73M Dec/2025